Prevalence of SARS‐CoV‐2 Antibodies in Kosovo‐Wide Population‐Based Seroepidemiological Study

ABSTRACT Background Seroprevalence studies have proven to be an important tool in tracking the progression of the coronavirus disease 2019 (COVID‐19) pandemic. The aim of this study was to measure the seroprevalence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) in the...

Full description

Saved in:
Bibliographic Details
Published inInfluenza and other respiratory viruses Vol. 18; no. 9; pp. e70004 - n/a
Main Authors Ramadani, Naser, Hoxha‐Gashi, Sanije, Gexha‐Bunjaku, Dafina, Kalaveshi, Arijana, Jakupi, Xhevat, Humolli, Isme, Vaughan, Aisling, Pebody, Richard, Kacaniku‐Gunga, Pranvera, Jashari, Violeta
Format Journal Article
LanguageEnglish
Published England John Wiley & Sons, Inc 01.09.2024
John Wiley and Sons Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:ABSTRACT Background Seroprevalence studies have proven to be an important tool in tracking the progression of the coronavirus disease 2019 (COVID‐19) pandemic. The aim of this study was to measure the seroprevalence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) in the general population of Kosovo by gender, age group and region and among asymptomatic people. Method The Institute of Public Health of Kosovo conducted a cross‐sectional population‐based survey, aligned with the protocols of the WHO Unity Studies, from the beginning of May to the end of June 2021. Results The survey covered a total of 2204 people with a response rate of 91.8% (41.9% [923] males and 51.2% [1281] females). In May to June 2021, the prevalence of antibodies in the overall population (IgG antibodies ≥ 1.1) was 37.0%. Seroprevalence was 34.4% in men and 38.9% in women (p < 0.05), with the highest percentage (48.7%) found in the 60–69 years' age group. The overall prevalence of acute IgM antibodies (IgM ≥ 1.1) was 1% (95% CI: 0.7%–1.5%), with no significant difference between genders and the highest prevalence among participants of 60–69 years of age (1.6%; 95% CI: 0.7%–3.6%). Conclusion A high prevalence of antibodies against SARS‐CoV‐2 was found in Kosovo before the start of the vaccination campaign. However, the results of the survey suggested that, by the end of June 2021, a desirable level of protection from the SARS‐CoV‐2 virus had not been reached.
Bibliography:All references to Kosovo in this document should be understood to be in the context of the United Nations Security Council Resolution 1244 (1999).
This survey was financed by the WHO through the German Federal Ministry of Health (BMG) COVID‐19 Research and Development grant and was conducted jointly by the WHO and the Institute of Public Health, Pristina.
The author affiliated with the World Health Organization (WHO) is alone responsible for the views expressed in this publication, and they do not necessarily represent the decisions or policies of the WHO.
Funding
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Funding: This survey was financed by the WHO through the German Federal Ministry of Health (BMG) COVID‐19 Research and Development grant and was conducted jointly by the WHO and the Institute of Public Health, Pristina.
ISSN:1750-2640
1750-2659
1750-2659
DOI:10.1111/irv.70004